



Reference List | 2021

TellBio Inc. is a development stage biotechnology company with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutics platform, TellDx and TellRx, respectively. TellBio's vision is to free patients and their families from the tyranny of cancer via both its TellDx and TellRx platforms.

The foundation of the Company's approach – detection of and targeting CTCs – is exclusively licensed from Massachusetts General Hospital and is based on decades of academic and clinical research. Following is a select list of references highlighting the academic and clinical research related to the CTC iChip:

Technology

- Fachin F, Spuhler P, Martel-Foley JM, et al. Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. *Sci Rep* 2017; 7(1):10936 | PMID: [28883519](#)
- Karabacak NM, Spuhler PS, Fachin F, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. *Nat Protoc* 2014; 9(3):694-710 | PMID: [24577360](#)
- Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. *Sci Transl Med* 2013; 5(179):179ra47 | PMID: [23552373](#)

CTCs Culture

- Hong X, Roh W, Sullivan RJ, et al. The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. *Cancer Discov* 2021; 11(3):678-695 | PMID: [33203734](#)
- Drapkin BJ, George J, Christensen CL, et al. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. *Cancer Discov* 2018; 8(5):600-615 | PMID: [29483136](#)
- Jordan NV, Bardia A, Wittner BS, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. *Nature* 2016; 537(7618):102-106 | PMID: [27556950](#)



- Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. *Science* 2014; 345(6193):216-220 | PMID: [25013076](#)

Single Cell Sequencing of CTCs

- Ebright RY, Lee S, Wittner BS, et al. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. *Science* 2020; 367(6485):1468-1473 | PMID: [32029688](#)
- Aceto N, Bardia A, Wittner BS, et al. AR Expression in Breast Cancer CTCs Associates with Bone Metastases. *Mol Cancer Res* 2018; 16(4):720-727 | PMID: [29453314](#)
- Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. *Science* 2015; 349(6254):1351-1356 | PMID: [26383955](#)
- Ting DT, Wittner BS, Ligorio M, et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. *Cell Rep* 2014; 8(6):1905-1918 | PMID: [25242334](#)

RNA-Based CTC detection in blood

- Hong X, Sullivan RJ, Kalinich M, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. *Proc Natl Acad Sci USA* 2018; 115(10):2467-2472 | PMID: [29453278](#)
- Kwan TT, Bardia A, Spring LM, et al. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. *Cancer Discov* 2018; 8(10):1286-1299 | PMID: [30104333](#)
- Miyamoto DT, Lee RJ, Kalinich M, et al. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. *Cancer Discov* 2018; 8(3):288-303 | PMID: [29301747](#)
- Kalinich M, Bhan I, Kwan TT, et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. *Proc Natl Acad Sci USA* 2017; 114(5):1123-1128 | PMID: [28096363](#)

